Vaccine Study for Surgically Resected Pancreatic Cancer
Completed
To assess the response for subjects with pancreatic cancer that have undergone surgical resection and treatment with a vaccine given with chemotherapy and chemoradiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2020
Locations: University of Minnesota Cancer Center, Minneapolis, Minnesota
Conditions: Pancreatic Cancer
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
Completed
Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection often goes away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. If a woman is not infected by HPV, it is very unlikely that she will get... Read More
Gender:
FEMALE
Ages:
Between 15 years and 25 years
Trial Updated:
07/02/2018
Locations: GSK Investigational Site, Minneapolis, Minnesota
Conditions: Infections, Papillomavirus
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma
Completed
RATIONALE: Aldesleukin may stimulate the white blood cells to kill tumor cells. Vaccines may help the body build an effective immune response to kill tumor cells. Giving aldesleukin together with vaccine therapy may kill more tumor cells. It is not yet known whether aldesleukin is more effective with or without vaccine therapy in treating melanoma. PURPOSE: This randomized phase II trial is studying how well aldesleukin works when given with or without vaccine therapy in treating patients with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2017
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Stage IV Melanoma
Influenza Vaccine Post Allogeneic Transplant
Terminated
Study Design: This is a randomized, single center study to evaluate immune responses to the seasonal influenza vaccine in allogeneic hematopoietic stem cell transplant (HSCT) recipients who receive one vaccine or two vaccine doses one month apart. In addition, a cohort of healthy adult volunteers will be recruited as controls to confirm immune response to a single influenza vaccine.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
12/03/2017
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Hematopoietic Stem Cell Transplant, Hematologic Malignancy
Efficacy of NicVAX in Smokers Who Want to Quit Smoking
Completed
The purpose of this study is to determine whether vaccination with NicVAX will result in a higher continuous abstinence rate than vaccination with placebo in smokers who want to quit smoking. In addition, two different formulations and dosing schedules will be studied, to select the dose and dosing schedule which generates the highest level of anti-nicotine antibodies. The primary study period is 12 months, which was extended by amendment to include up to 2 years of observations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/11/2017
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Smoking Cessation
Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease
Completed
Pneumococcal disease is a serious bacterial infection that can affect different parts of the body, including the lungs. People with chronic illnesses, such as chronic obstructive pulmonary disease (COPD), have a greater risk of developing pneumonia and meningitis as a result of pneumococcal disease. This study will compare the immune response to two types of pneumococcal vaccines in adults with COPD.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/22/2015
Locations: Veteran's Administration Medical Center, Minneapolis, Minnesota +2 locations
Conditions: Pulmonary Disease, Chronic Obstructive
Increasing HAART-Induced Immune Restoration With Cyclosporine
Completed
The purpose of this study is to see if cyclosporine, taken when a patient begins highly active antiretroviral therapy (HAART), increases the number of CD4 T-cells (blood cells that fight infection) in a patient's blood. This study also will explore the safety of briefly giving cyclosporine to patients starting HAART.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2015
Locations: Univ of Minnesota, Minneapolis, Minnesota
Conditions: HIV Infections
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
Terminated
RATIONALE: Vaccines made from tumor tissue may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV ovarian epithelial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/10/2013
Locations: University of Minnesota Cancer Center, Minneapolis, Minnesota
Conditions: Ovarian Cancer
NicVAX/Placebo as an Aid for Smoking Cessation
Completed
The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2012
Locations: NicVAX Investigator, Minneapolis, Minnesota
Conditions: Smoking Cessation, Smoking, Tobacco Cessation
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
Completed
The purpose of this study is to find out whether these powerful combinations of anti-HIV drugs are safe and effective for use in patients in the early stages of HIV infection and to find out how patients' immune systems react to HIV and anti-HIV drugs. Doctors generally treat patients in the early stages of HIV infection with the same anti-HIV drugs taken by patients who have had HIV for a long time. These drugs lower the level of HIV in the blood. However, doctors do not know whether patients... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
03/01/2011
Locations: Univ of Minnesota, Minneapolis, Minnesota
Conditions: HIV Infections